J Clin Oncol: Where should the first-line treatment of metastatic pancreatic cancer go?

Although medical technology continues to develop, the current prognosis of metastatic pancreatic cancer (mPC) is still poor, with a 5-year survival rate of <5%

This is a phase II study in which mPC patients were randomly assigned to receive FOLFIRINOX for 6 months (group A), FOLFIRINOX for 4 months, followed by leucovorin + fluorouracil maintenance therapy (group B), or alternate every 2 months Sequential treatment of gemcitabine and fluorouracil, folinic acid and irinotecan (group C)

Survival period of patients in each treatment group

January 2015 --2016 November recruited 276 patients (mean 63 years; range 40-76 years): A group 91, group B 92 bits C 90 group bit

Survival period of patients whose quality of life scores do not deteriorate in different treatment groups

In summary, for mPC patients whose condition is under control after 4 months of FOLFIRINOX induction chemotherapy, maintenance therapy with folinic acid + fluorouracil seems to be feasible and effective

Dahan et al.